Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers

OBJECTIVE: Topotecan at a dose of 1.5 mg/m(2) on days 1 to 5 of a 21-day cycle is an approved therapy for recurrent ovarian cancer. However, heavily pretreated patients may be predisposed to hematologic adverse events. This prospective study, therefore, investigates the safety and efficacy of an alt...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Morris, Robert, Alvarez, Ronald D., Andrews, Stephen, Malone, John, Bryant, Christopher, Heilbrun, Lance K., Smith, Daryn, Schimp, Veronica, Munkarah, Adnan
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2008
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3865862/
https://ncbi.nlm.nih.gov/pubmed/18410954
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2008.02.028
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller